Literature DB >> 20708879

Secretory phospholipase A2: a marker of infection in febrile children presenting to a pediatric ED.

Karim M Mansour1, Frans A Kuypers, Tammy N Wang, Annabeth M Miller, Sandra K Larkin, Claudia R Morris.   

Abstract

BACKGROUND: Fever is a common presenting complaint to the emergency department (ED), and the evaluation of the febrile child remains a challenging task.
OBJECTIVE: The aim of this study was to examine the relationship between secretory phospholipase A2 (sPLA2) and infection in febrile children.
METHODS: A prospective convenience sample of children presenting with fever to an urban pediatric ED were studied. Blood and urine cultures, a complete blood count, and serum concentrations of sPLA2 were obtained, and patients were compared based on their final diagnosis of either a viral or bacterial infection.
RESULTS: In the 76 patients enrolled, 60 were diagnosed with a viral infection, 14 with a bacterial infection, 1 with Kawasaki disease, and 1 with acute lymphoblastic leukemia. The difference in the serum concentration of sPLA2 in patients with viral infections (22 ± 34 ng/mL) versus those with bacterial infections (190 ± 179 ng/mL) was statistically significant (P < .0001). Receiver operator characteristic curve analysis revealed that sPLA2 was more accurate at predicting bacterial infection (area under the curve = 0.89) than the total white blood cell count (area under the curve = 0.71) and that a value of more than 20 ng/mL had a sensitivity of 93%, specificity of 67%, positive predictive value of 39%, and negative predictive value of 97%.
CONCLUSION: Secretory phospholipase A2 differs significantly in children with viral versus bacterial infection and seems to be a reliable screening test for bacterial infection in febrile children.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708879      PMCID: PMC3601899          DOI: 10.1016/j.ajem.2010.06.024

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  31 in total

Review 1.  Management of fever without source in infants and children.

Authors:  L J Baraff
Journal:  Ann Emerg Med       Date:  2000-12       Impact factor: 5.721

2.  C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection.

Authors:  P N Pulliam; M W Attia; K M Cronan
Journal:  Pediatrics       Date:  2001-12       Impact factor: 7.124

3.  Secretory phospholipase A2 activity correlates with postinjury multiple organ failure.

Authors:  D A Partrick; E E Moore; C C Silliman; C C Barnett; F A Kuypers
Journal:  Crit Care Med       Date:  2001-05       Impact factor: 7.598

4.  Early identification of bacteremia by biochemical markers of systemic inflammation.

Authors:  E M Rintala; J Aittoniemi; S Laine; T J Nevalainen; J Nikoskelainen
Journal:  Scand J Clin Lab Invest       Date:  2001       Impact factor: 1.713

5.  Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center.

Authors:  Annick Galetto-Lacour; Samuel A Zamora; Alain Gervaix
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

6.  Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker.

Authors:  Anna Fernández Lopez; C Luaces Cubells; J J García García; J Fernández Pou
Journal:  Pediatr Infect Dis J       Date:  2003-10       Impact factor: 2.129

7.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

8.  Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen?

Authors:  Bema K Bonsu; Mb Chb; Marvin B Harper
Journal:  Ann Emerg Med       Date:  2003-08       Impact factor: 5.721

9.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Sheldon L Kaplan; Edward O Mason; Ellen R Wald; Gordon E Schutze; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Ram Yogev; William J Barson
Journal:  Pediatrics       Date:  2004-03       Impact factor: 7.124

10.  Utility of the serum C-reactive protein for detection of occult bacterial infection in children.

Authors:  Daniel J Isaacman; Bonnie L Burke
Journal:  Arch Pediatr Adolesc Med       Date:  2002-09
View more
  4 in total

Review 1.  Hyperinflammation, apoptosis, and organ damage.

Authors:  Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-27

Review 2.  Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review.

Authors:  Anokhi J Kapasi; Sabine Dittrich; Iveth J González; Timothy C Rodwell
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

3.  Measurement of a Novel Biomarker, Secretory Phospholipase A2 Group IIA as a Marker of Sepsis: A Pilot Study.

Authors:  Elena Berg; Janel Paukovits; Jennifer Axelband; Jonathan Trager; Dina Ryan; Kathleen Cichonski; Mark Kopnitsky; Daniel Zweitzig; Rebecca Jeanmonod
Journal:  J Emerg Trauma Shock       Date:  2018 Apr-Jun

4.  Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C).

Authors:  Frans A Kuypers; Christina A Rostad; Evan J Anderson; Ann Chahroudi; Preeti Jaggi; Jens Wrammert; Grace Mantus; Rajit Basu; Frank Harris; Bradley Hanberry; Andres Camacho-Gonzalez; Shaminy Manoranjithan; Miriam Vos; Lou Ann Brown; Claudia R Morris
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.